The case for & against
Bull & Bear analysis
Bullish
AFT Pharmaceuticals Limited (ASX:AFP, NZX:AFT) is an emerging pharmaceutical company engaged in the development, manufacturing, and commercialization of innovative healthcare products, particularly focusing on prescription and over-the-counter medicines. The company is gaining traction in the healthcare sector, emphasizing product development and expansion into international markets. AFT is well-positioned within the broader theme of increasing healthcare demand and advancements in pharmaceutical R&D, particularly with an emphasis on injectables and targeted therapies.
Bull says
- ↑FY26 revenue NZ$254.7m (+22% YoY), driven by 66% international and 41% Asia growth
- ↑Operating profit NZ$24.4m; net profit NZ$14.1m (+24% YoY) underscores strong margins
- ↑R&D spend to rise to NZ$25m in FY27 from NZ$18m, boosting late-stage pipeline
- ↑Guidance for FY27: >NZ$300m revenue and NZ$28–32m operating profit signals confidence
- ↑Licensing income reached NZ$3.1m; broad market demand supports expansion
- ↑Favorable factors: high earnings yield, strong cash-flow profile, positive momentum, high ROE
Bear says
- ↓R&D and product launch delays risk missing FY27 targets and pressuring earnings
- ↓Regulatory shifts and intense competition may hinder market penetration
- ↓Dependence on key products risks revenue if approvals or safety issues arise
- ↓High R&D costs create value trap concerns if growth targets slip
- ↓Unfavorable factors: poor earnings yield, weak cash flow ratio, high short interest
- ↓Market volatility and macro headwinds could amplify downside